Fibroblast activation protein-targeted radiopharmaceuticals: Recent trends in cancer diagnosis

Fibroblast activation protein (FAP), widely overexpressed in the tumor stroma of various cancers, has emerged as a promising target for cancer imaging. Radiopharmaceuticals designed to target FAP offer significantly improved tumor-to-background contrast compared to traditional imaging agents, thereby enhancing the precision of cancer detection. This review summarizes recent advancements in FAP-targeted diagnosis radiopharmaceuticals, highlighting their advantages and future potential.